Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CB-839 HCl, Carfilzomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT03798678Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2019
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of telaglenastat in multiple myeloma (MM), sponsored by National Cancer Institute. Primary endpoint: Maximum Tolerated Dose and Recommended Phase II Dose up to 28 days. Started Jul 2019; status: active, not recruiting.
02
Drugs
telaglenastat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03798678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03798678.